Dataset from A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009490
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus
placebo on exercise ability using the 6 minute walk test in patients with chronic HF with
reduced ejection fraction (LVEF ≤ 40%) Secondary objectives are to assess Patient-Reported
Outcome (PRO)
创建时间：
2024-11-26
